PMKB
PMKB
Genes
Variants
Interpretations
Tumor Types
Primary Sites
Activity
Login
KIT
Information
View History
Pending Review
Interpretation 2211
Tier 1
KIT
Variants
KIT D820Y
KIT D820G
Primary Sites
Unknown
Tumor Types
Gastrointestinal Stromal Tumor
Interpretation
Nilotinib Dasatinib Sorafenib Regorafenib Sunitinib
Citations
Reichardt P, et al. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol 2012;23(7):1680-7
Thomas A, et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol 2015;16(2):177-86
Montemurro M, et al. Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis. Eur J Cancer 2013;49(5):1027-31
Last updated: 2018-04-18 14:14:16 UTC
PMKB Bot
Genes
Variants
Interpretations
Tumor Types
Primary Sites
Activity